Baxter BioPharma Solutions recently completed the lyophilization capacity expansion at their cytotoxic contract manufacturing facility in Halle, Germany. The expansion increased their total cytotoxic lyophilization capacity to four dedicated lyophilizers and more than 1,100 sq.-ft. The expansion was designed to meet EU, U.S. and JP requirements. Two large-scale lyophilization units were added to freeze-dry clients’ cancer therapy drugs. The expansion includes technologies to safely handle...